Arthritis Clinical Trials in Austin
View 12 new treatments for Arthritis in Austin, TX, and nearby areas, such as Round Rock. Every day, Power helps hundreds of arthritis patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Guselkumab for Psoriatic Arthritis
Janssen Clinic, Austin + 1 more
This trial is testing guselkumab, a medication that reduces inflammation, in patients with psoriatic arthritis affecting the spine. It works by blocking a protein called IL-23 to help reduce symptoms and inflammation. Guselkumab is the first IL-23 specific inhibitor approved for the treatment of moderate-to-severe psoriasis.Show More
Recruiting
Phase 4
Est. 3 - 12 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
Adalimumab Discontinuation for Uveitis
Research Clinic, Austin + 1 more
The proposed study is a stratified, block-randomized, double-masked, controlled trial to determine the feasibility of discontinuing adalimumab treatment in patients with quiescent uveitis associated with juvenile idiopathic arthritis (JIA) or chronic anterior uveitis (CAU).Show More
Waitlist
Phase 4
Est. 3 - 6 Weeks
Nisha Acharya, MD MS
Principal Investigator
Bimekizumab for Psoriatic Arthritis
UCB Biopharma Clinic, Austin + 1 more
This trial is testing the safety and effectiveness of bimekizumab, a medication given as an injection under the skin. It is aimed at adults who have psoriatic arthritis, a condition that causes joint pain and swelling. Bimekizumab works by blocking proteins that cause inflammation, helping to reduce pain and swelling.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
UCB Cares
Study Director
Tildrakizumab for Psoriatic Arthritis
Sun Clinic, Austin + 1 more
This trial is testing tildrakizumab, a medication that reduces inflammation, in patients with active Psoriatic Arthritis who haven't tried certain other treatments. It works by blocking a protein to help manage symptoms. Tildrakizumab is approved for treating moderate to severe plaque psoriasis.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team
Upadacitinib for Axial Spondyloarthritis
AbbVie Clinic, Austin + 1 more
This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently. The main objectives of this protocol are: * To evaluate the efficacy of upadacitinib compared with placebo on reduction of signs and symptoms in adults with active axial spondyloarthritis (axSpA) including biologic disease-modifying antirheumatic drug inadequate responders (bDMARD-IR) ankylosing spondylitis (AS) (Study 1) and non-radiographic axial spondyloarthritis (nr-axSpA) (Study 2). * To assess the safety and tolerability of upadacitinib in adults with active axSpA including bDMARD-IR AS (Study 1) and nr-axSpA (Study 2). * To evaluate the safety and tolerability of upadacitinib in extended treatment in adult participants with active axSpA including bDMARD-IR AS who have completed the Double-Blind Period (Study 1) and nr-axSpA who have completed the Double-Blind Period (Study 2). * To evaluate the maintenance of disease control after withdrawal of upadacitinib.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
ABBVIE INC.
Study Director
Upadacitinib for Psoriatic Arthritis
AbbVie Clinic, Austin + 1 more
The study objectives of Period 1 are to compare the efficacy, safety, and tolerability of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo for the treatment of signs and symptoms in adults with moderately to severely active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to biologic disease-modifying anti-rheumatic drug (bDMARD). The objective of Period 2 is to evaluate the long-term safety, tolerability and efficacy of upadacitinib 15 mg QD and 30 mg QD in participants who have completed Period 1.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
AbbVie Inc.
Study Director
Risankizumab for Psoriatic Arthritis
AbbVie Clinic, Austin + 1 more
The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
Waitlist
Phase 3
Est. 6 - 12 Weeks
AbbVie Inc.
Study Director
Amniotic Suspension Allograft for Knee Osteoarthritis
Organogenesis Clinic, Austin + 1 more
This trial is testing if injecting ASA into the knee can help people with knee osteoarthritis feel better. The study will check pain levels, knee function, and safety over several months. ASA (Amniotic Suspension Allograft) has been shown to be an effective treatment for knee osteoarthritis in previous studies.Show More
Recruiting
Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team
RTX-GRT7039 Injection for Osteoarthritis
Grünenthal Clinic, Austin + 1 more
This trial tests a special injection called RTX-GRT7039 to help reduce knee pain in people with osteoarthritis who still have pain despite usual treatments. The injection works by blocking pain signals from the knee.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team
Retatrutide for Obesity
Eli Lilly Clinic, Austin + 1 more
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
Study Director
Page 1 of 4
Frequently Asked Questions
Explore related conditions